Octreotride
I'll look up octreotide from the medical library for you.
Searching sources...
Reading File
Now I'll search the medical library for octreotide in parallel:
Finding Sources
Finding Sources
Excellent - multiple rich sources found. Let me read the key sections in parallel:
Reading File
Reading File
Reading File
Now let me get the GI bleeding / varices data and the neuroendocrine/carcinoid sections:
Reading File
Reading File
I now have comprehensive data from multiple authoritative pharmacology and GI textbooks. Here is a complete overview:
Octreotide
What Is It?
Octreotide is a synthetic octapeptide analogue of somatostatin (the natural 14-amino-acid regulatory peptide). It was developed to overcome somatostatin's extremely short half-life of ~3 minutes. Octreotide retains somatostatin's key biological actions but with much greater potency and durability.
- Potency: 45x more potent than somatostatin in inhibiting growth hormone (GH) release, but only 2x as potent in reducing insulin secretion - this relative sparing of the pancreatic beta cell is clinically important
- Receptor binding: Binds preferentially to somatostatin receptor subtypes SST2 and SST5
Pharmacokinetics
| Route | Half-life | Duration | Dose |
|---|---|---|---|
| IV | 80-120 min | Short (effect on portal pressure not prolonged) | 50 µg bolus + 50 µg/hr infusion |
| Subcutaneous | ~80-90 min | 6-12 hours | 50-200 µg every 8 hours |
| IM depot (LAR) | Long-acting | Monthly (every 4 weeks) | 10-40 mg IM |
- SC octreotide (100 µg TID): 100% bioactive, peak effect within 30 min
- The LAR (long-acting release) microsphere depot form is given once monthly - it is only started after the patient has been confirmed to tolerate and respond to short-acting octreotide
Mechanism of Action
Octreotide acts via somatostatin receptors (SST2/SST5) to produce the following effects:
- Inhibits hormone secretion: gastrin, CCK, glucagon, growth hormone, insulin, secretin, pancreatic polypeptide, VIP, and serotonin (5-HT)
- Reduces intestinal fluid and pancreatic secretion
- Slows GI motility (at higher doses) - stimulates motility at low doses (~50 µg)
- Reduces portal and splanchnic blood flow (via glucagon inhibition)
- Inhibits anterior pituitary hormone secretion (GH, TSH)
Clinical Uses
1. Neuroendocrine Tumors (NET)
- Carcinoid tumor: Octreotide (50-200 µg SC q8h) dramatically reduces secretory diarrhea, flushing, and wheezing by inhibiting serotonin and other mediators. LAR formulations allow monthly dosing for long-term symptom control.
- VIPoma: Reduces profuse secretory diarrhea (Verner-Morrison syndrome)
- Acromegaly: Suppresses GH/IGF-1 levels; goal is GH <2.5 ng/mL. LAR 10-30 mg IM every 4 weeks. Can also cause modest reduction in pituitary tumor size.
- Gastrinoma, glucagonoma, insulinoma, ACTH-secreting tumor: Symptom control
2. GI Bleeding / Portal Hypertension
- Esophageal variceal bleeding: IV bolus 50 µg then 50 µg/hr infusion for 2-5 days, started before endoscopy. Reduces splanchnic blood flow and portal pressure. Combined with endoscopic variceal ligation (EVL). Evidence suggests equivalence to terlipressin or sclerotherapy for acute variceal control.
- Somatostatin receptor scintigraphy: Radiolabeled octreotide is used to localize neuroendocrine tumors (Octreoscan) and predicts response to octreotide therapy
3. Diarrheal Conditions
- Secretory diarrhea, HIV-associated diarrhea, diabetic diarrhea
- Chemotherapy- or radiation-induced diarrhea
- Short-bowel syndrome, dumping syndrome, post-vagotomy diarrhea
4. Other Uses
- Pancreatic fistula: Reduces pancreatic secretion
- Small bowel bacterial overgrowth / intestinal pseudo-obstruction (scleroderma): Low-dose (50 µg SC) stimulates motility
- Cushing disease: Pasireotide (a related analogue with higher SST5 affinity) is preferred here
Adverse Effects
| System | Effect |
|---|---|
| GI | Nausea, vomiting, abdominal cramps, flatulence, steatorrhea (from impaired pancreatic secretion) |
| Biliary | Gallstones / biliary sludge in 20-30% at 1 year, up to >50% at 5 years (due to inhibition of gallbladder contraction); rarely leads to acute cholecystitis |
| Endocrine | Hyperglycemia (usually mild) from altered insulin/glucagon/GH balance; less commonly hypoglycemia; hypothyroidism (inhibited TSH) |
| Cardiac | Sinus bradycardia (~25%), conduction disturbances (~10%), QT prolongation (especially in underlying cardiac disease) |
| Nutritional | Steatorrhea → fat-soluble vitamin deficiency; Vitamin B12 deficiency with long-term use |
| Local | Pain at injection site (especially with LAR formulation) |
Comparison With Other Somatostatin Analogues
| Drug | Key Feature |
|---|---|
| Octreotide | Most widely used; SST2/SST5 affinity; IV, SC, or monthly LAR |
| Lanreotide | Deep SC autogel every 4 weeks; comparable efficacy to octreotide LAR for acromegaly |
| Pasireotide | Binds SST1/2/3/5 (highest affinity SST5); approved for Cushing disease and acromegaly; significantly worsens glucose tolerance (decreases GLP-1, GIP, and insulin secretion) |
Key Points to Remember
- Octreotide is somatostatin's long-acting synthetic analogue (8 amino acids vs 14)
- Short-acting SC form is confirmed first; LAR is only introduced once tolerance is established
- Gallstones are the most common serious long-term complication (>50% at 5 years)
- In variceal bleeding: initiate before endoscopy, combine with EVL
- Dose-dependent effect on motility: low dose stimulates, high dose inhibits intestinal motility
Sources: Katzung's Basic and Clinical Pharmacology 16th ed. | Goodman & Gilman's Pharmacological Basis of Therapeutics | Sleisenger & Fordtran's GI and Liver Disease | Current Surgical Therapy 14th ed.
photo-1783884432522.jpg
Make an explanation about this for my thesis
Asking for Preferences
What is the main topic/title of your thesis? · What should the explanation focus on?
Here is a ready-to-use thesis paragraph explaining Table 1:
Observation
Table 1 presents the incidence of breast disorders among patients admitted during the study period, with a total sample size of 100 cases (n=100).
During the study period, the hospital recorded a total of 116,081 admissions across all departments, of which the study cases constituted a negligible proportion (0.087%), reflecting the selective and focused nature of the study population. Among all admissions, 11,795 patients (0.85%) were admitted under the Surgery Department, indicating that surgical conditions accounted for less than one percent of the overall hospital burden.
Of the total surgical admissions, 4,849 (2.06%) were female patients, underscoring the comparatively lower yet clinically significant proportion of women seeking surgical care. This subset forms the denominator from which breast disorder cases were drawn, as breast pathology predominantly - though not exclusively - affects the female population.
A total of 175 patients were diagnosed with a breast disorder, representing 57% of female surgical admissions. This is a notably high proportion, suggesting that breast disorders constitute a major indication for surgical consultation among female patients at this institution. The finding highlights the considerable burden of breast disease within the surgical outpatient and inpatient setting, and reinforces the need for dedicated diagnostic and management pathways for this condition.
Taken together, these figures demonstrate that while breast disorders represent only a small fraction of total hospital admissions, they account for a disproportionately large share of female surgical workload - a pattern consistent with the global epidemiological trend of breast disease as one of the leading surgical conditions in women.
Note: You may adjust the phrase "this institution" to your actual hospital name, and "study period" to the specific dates of your data collection. Let me know if you need this formatted differently or expanded with additional sections.
Basal pulse rate and sleeping pulse rate
Basal pulse rate is the heart rate measured after complete rest (typically first thing in the morning before getting out of bed), while sleeping pulse rate is the lowest heart rate recorded during sleep. They are closely related but not identical - sleeping HR is usually 1-5 bpm lower than basal.
Searching sources...
Finding Sources
Finding Sources
Searching the Web
basal pulse rate vs sleeping pulse rate difference physiology
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is a thorough comparison:
Basal Pulse Rate vs. Sleeping Pulse Rate
Definitions
| Term | Definition |
|---|---|
| Basal (Resting) Pulse Rate | Heart rate measured when a person is awake, in a calm, thermoneutral environment, having had no recent exertion, food, stress, or stimulation - typically measured first thing in the morning before rising from bed |
| Sleeping Pulse Rate | Heart rate recorded during sleep - it varies across sleep stages and reaches its lowest point during deep (N3) NREM sleep |
These are related but not the same. The sleeping heart rate is generally 20-30% lower than the daytime resting/basal rate (Cleveland Clinic).
Normal Values
| State | Normal Range (Adults) |
|---|---|
| Basal / Resting HR | 60-100 bpm (AHA standard) |
| Sleeping HR (general) | 50-75 bpm |
| Sleeping HR (deep sleep, N3) | 40-50 bpm (can be lower in athletes) |
| Intrinsic SA node rate (denervated) | ~100 bpm |
- Athletes and highly fit individuals may have a basal HR as low as 37-38 bpm
- During sleep, 40-50 bpm is common and considered physiologically normal
- During REM sleep, HR can rise back near waking levels
Physiology: Why Does HR Fall During Sleep?
1. Autonomic Control - The Core Mechanism
The SA node fires at 60-100 bpm at rest, but this is already suppressed below its intrinsic rate (~100 bpm) by resting parasympathetic (vagal) tone. During sleep, parasympathetic dominance increases further, slowing HR even more.
"The autonomic nervous system exhibits control over the sinus node, with a preponderance of parasympathetic innervation at baseline. Removal of parasympathetic tone or an increase in sympathetic innervation leads to an increase in rate of depolarization."
- Harrison's Principles of Internal Medicine, 22nd ed.
2. Sleep Stage-Dependent Changes
| Sleep Stage | Autonomic State | Heart Rate Effect |
|---|---|---|
| N1 (Light NREM) | Sympathetic activity begins to fall | HR starts declining |
| N2 (Light-Moderate NREM) | Parasympathetic tone increases | HR falls further |
| N3 (Deep / Slow-wave NREM) | Sympathetic at nadir; parasympathetic dominant | HR at its lowest - most "restful" for heart |
| REM Sleep | Sympathetic bursts; autonomic instability | HR rises, becomes irregular - can approach waking levels |
"NREM sleep is characterized by autonomic stability due to a simultaneous decrease in sympathetic nervous system activity and elevated parasympathetic neural tone, which progressively increases with the deepening of sleep stages from N1 to N3. Consequently, arterial BP and heart rate decrease progressively throughout NREM sleep, decreasing cardiac workload and metabolic rate."
- Fuster & Hurst's The Heart, 15th ed.
"In contrast to NREM sleep, REM sleep is associated with dreaming, is emotional, and provokes increased sympathetic activity with consequent increased heart rate and BP."
- Fuster & Hurst's The Heart, 15th ed.
"Blood pressure and heart rate decrease during NREM sleep, particularly during N3 sleep. During REM sleep, bursts of eye movements are associated with large variations in both blood pressure and heart rate mediated by the autonomic nervous system."
- Harrison's Principles of Internal Medicine, 22nd ed.
Key Differences Side by Side
| Feature | Basal Pulse Rate | Sleeping Pulse Rate |
|---|---|---|
| State | Awake, calm, resting | Asleep |
| Consciousness | Conscious | Unconscious |
| Typical value | 60-100 bpm | 40-75 bpm |
| Lowest point | At complete rest (morning) | During N3 deep sleep |
| ANS tone | Mild vagal predominance | Strong vagal predominance (NREM); sympathetic bursts (REM) |
| Variability | Relatively stable | Fluctuates with sleep cycle (~90-min cycles) |
| Measurement | Manual, lying quietly | Wearable monitor / polysomnography |
| Clinical use | Fitness indicator, cardiovascular risk assessment | Sleep quality, autonomic function, arrhythmia detection |
Clinical Significance
- Low basal HR (well-trained athletes): reflects high vagal tone and cardiac efficiency - a sign of fitness
- High basal HR (>80-90 bpm): associated with increased cardiovascular risk, diabetes, and mortality
- Failure of HR to drop during sleep ("non-dipping"): indicates autonomic dysfunction, associated with hypertension, OSA, and increased cardiac events
- Nocturnal bradycardia (HR <40 bpm during sleep): can be normal in athletes, but warrants evaluation in symptomatic individuals
- Nocturnal tachycardia (HR >100 bpm during sleep): can indicate sleep apnea, fever, heart failure, arrhythmia, or anxiety
- REM-associated arrhythmias: Cardiac dysrhythmias occur selectively during REM sleep due to autonomic instability - relevant in OSA and coronary artery disease patients
Summary
- Basal pulse rate = the floor of your awake HR, controlled by resting vagal tone on the SA node
- Sleeping pulse rate = drops further than basal, reaching its nadir in N3 deep sleep, then rebounds during REM
- Both reflect autonomic health - a healthy heart should show a clear nocturnal dip in HR
- The sleeping HR is the best single indicator of true cardiovascular rest
Sources: Harrison's Principles of Internal Medicine 22nd ed. | Fuster & Hurst's The Heart 15th ed. | Cleveland Clinic | Sleep Foundation
This is a shared conversation. Sign in to Orris to start your own chat.